The next stage

The 90-day period to submit comments on the draft interoperability roadmap came to a close one week ago, and lots of stakeholders had lots to say about it.

The Office of the National Coordinator for Health IT's (ONC) draft interoperability roadmap drew a wide range of support and criticism as the public comment period came to a close on April 3. 

The American Hospital Association said it supported ONC's goal of creating an interoperable health IT infrastructure but raised concern that EHR system technology does not support seamless data exchange. The group cited the cost and complexity of the interfaces needed to connect systems, which are not sustainable.

The American Medical Association’s recommendations included acknowledgement of the effect of Meaningful Use on interoperability, addressing barriers to interoperability, avoiding a disciplinary approach on providers and prioritizing “cornerstone” issues such as functional standards and clinical data definitions.

The Workgroup for Electronic Data Interchange (WEDI) called on ONC to “better reflect the realities, gaps, challenges and opportunities across the current landscape.” The organization also declared the roadmap’s scope and timing “aggressive.”

WEDI also noted a need to move from government oversight to industry involvement. While ONC has "played a key role in driving the development and adoption of core building blocks and standards for health information technology,” the nation is moving "into a more mature phase of building a health IT infrastructure." WEDI cited the success of Healtheway as one example of how public-private collaboration can drive efforts forward.

It will be interesting to see how the roadmap changes between this draft and the final version. 

Beth Walsh

Clinical Innovation + Technology editor

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.